SCHEDULE: FMR LLC Discloses 15% Stake in CAMP4 Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in CAMP4 Therapeutics Corp. common stock as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 3,023,434 shares of CAMP4 Therapeutics Corp. common stock.
- This ownership represents 15.0% of the total outstanding common stock of CAMP4 Therapeutics Corp.
- The reporting date for this ownership stake was September 30, 2025.
- FMR LLC holds sole voting power over 3,022,105 shares and sole dispositive power over 3,023,434 shares.
- Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same aggregate amount of shares through her association with FMR LLC.
- A portion of this interest, specifically 1,463,592 shares (7.3% of outstanding common stock), is held by Select Biotechnology Portfolio.
Sentiment
Score: 7
Explanation: The disclosure of a significant 15.0% beneficial ownership by a major institutional investor like FMR LLC is generally viewed positively, indicating strong investor confidence in the company's prospects. While not a performance report, it suggests a substantial commitment from a respected financial entity.
Positives
- Significant institutional investment by FMR LLC, a major financial services firm, indicates confidence in CAMP4 Therapeutics Corp.
- A 15.0% stake suggests a substantial long-term interest from a prominent investor.
Future Outlook
No forward-looking statements or guidance regarding the company's future performance or strategic direction are provided.
Industry Context
The disclosure of a significant 15.0% stake by FMR LLC, a leading global asset manager, in a biotechnology company like CAMP4 Therapeutics Corp. highlights continued institutional interest in the life sciences sector. Such investments often signal a belief in the long-term growth potential of companies developing innovative therapies, aligning with broader trends of capital allocation towards promising biotech ventures.
Stakeholder Impact
- Shareholders: Increased institutional ownership may enhance investor confidence and potentially stabilize the stock price.
- Management: A significant institutional stake could lead to increased scrutiny or engagement from the investor regarding strategic decisions.
Key Dates
| Date | Description |
|---|---|
| January 3, 2023 | Effective date of Power of Attorney for FMR LLC. |
| January 26, 2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| September 30, 2025 | Date of event requiring the filing of this statement (ownership threshold met/reporting period end date). |
| October 6, 2025 | Date of filing of this Schedule 13G. |
Recommendation
holdA significant institutional stake by FMR LLC is generally a positive signal of investor confidence. However, this report primarily details ownership and does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Without further financial or strategic updates from CAMP4 Therapeutics Corp., a 'hold' recommendation is prudent, acknowledging the positive signal of institutional interest while awaiting more comprehensive company-specific information.
Keywords
CAMP4 Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology Portfolio
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.